-
Formosa Pharmaceuticals and Eyenovia Inc. Sign Licensing Deal for Ocular Surgery Treatment
•
Taiwan’s Formosa Pharmaceuticals (TPE: 6838) and US-based Eyenovia Inc., (NASDAQ: EYEN) have signed their second licensing and partnership agreement. Under this deal, Eyenovia has acquired exclusive US rights to commercialize APP13007 (clobetasol propionate ophthalmic nanosuspension, 0.05%), a treatment for inflammation and pain following ocular surgery. The total value of the…
-
Eyenovia, Inc. Receives FDA Approval for Mydcombi, a First-of-Its-Kind Ophthalmic Spray
•
US-based Eyenovia, Inc. (NASDAQ: EYEN) has announced obtaining market approval from the US Food and Drug Administration (FDA) for its Mydcombi (tropicamide and phenylephrine hydrochloride ophthalmic spray) 1%/2.5%. This product is indicated for inducing mydriasis during diagnostic procedures and in conditions requiring short-term pupil dilation. A Milestone in Ophthalmic Drug…
-
Eyenovia Partners with Formosa Pharmaceuticals for Ophthalmic Therapeutics
•
US-based Eyenovia Inc., (NASDAQ: EYEN) has announced a strategic development and collaboration agreement with Taiwan-based Formosa Pharmaceuticals Inc., (TPE: 6838). The partnership aims to combine Eyenovia’s Optejet dispensing technology with Formosa’s unique APNT nanoparticle formulation platform, potentially leading to the development of new topical ophthalmic therapeutics that employ the Optejet…
